Screening for prostate cancer using multivariate mixed-effects models

Screening for prostate cancer using multivariate mixed-effects models.

Using several variables known to be related to prostate cancer, a multivariate classification method is developed to predict the onset of clinical prostate cancer. A multivariate mixed-effects model is used to describe longitudinal changes in prostate specific antigen (PSA), a free testosterone index (FTI), and body mass index (BMI) before any clinical evidence of prostate cancer. The patterns ...

PSA Screening in Prostate Cancer

Introduction: Prostate cancer is one of the most common cancers in Iranian men. PSA(prostate specific antigen) screening is a controversial issue because PSA screening leads to diagnose of patients with low risk prostate cancer who not only do not benefit from treatment but also suffer from complication caused by treatment. On the other hand, without prostate cancer screening, the rate of meta...

Using Multivariate Mixed-effects Models to Predict Hypertension

Effects of Prostate Cancer Screening Mandates on Prostate Cancer Mortality

Health insurance mandates are playing a bigger role in today’s society as state representatives see increased benefits of certain health products. After being introduced to the general public, the PSA test has been shown to increase the finding of prostate cancer incidence and preventatively reduce prostate cancer mortality. Today, there are 33 states that have enacted legislation to require ei...

Screening for prostate cancer.

In the United States, prostate cancer will affect 1 man in 6 during his lifetime. Since the mid-1980s, screening with the prostate-specific antigen (PSA) blood test has more than doubled the risk of a prostate cancer diagnosis. A decrease in prostate cancer death rates has been observed since that time, but the relative contribution of PSA testing as opposed to other factors, such as improved t...